Li Xuyan, Lin Suiling, Zhang Yuling, Wang Hongbiao
Department of Internal Medicine, Cancer Hospital of Shantou University Medical College, Shantou, Guangdong, China.
Department of prevention and health care, Cancer Hospital of Shantou University Medical College, Shantou, Guangdong, China.
Sci Rep. 2015 Aug 20;5:13335. doi: 10.1038/srep13335.
The present study investigated the treatment and survival outcomes of patients with synchronous primary esophageal squamous cell carcinoma and gastric adenocarcinoma. The medical records of 10,783 patients with primary esophageal squamous cancer treated at our institution between 1995 and 2012 were retrospectively reviewed. Overall survival (OS) rates were calculated using the Kaplan-Meier method. The incidence was 0.38% (41/10,783). Of these 41 patients, 26 underwent curative surgery, ten received palliative chemotherapy or radiotherapy, and five received no treatment. The median OS of the surgery, palliative-therapy, and treatment-free groups was 17.1, 9.0, and 3.8 months, respectively. The 1-, 3-, 5-, and 10-year OS rates for the surgery group were 77%, 45%, 33%, and 19%, respectively. No significant differences in median OS were observed between the surgery group and the historical cohort of isolated esophageal cancer (n = 186) (17.1 vs. 21.0 months, P = 0.061) or isolated gastric cancer (n = 51) (17.1 vs. 28.9 months, P = 0.875), or between the palliative-therapy group and its corresponding historical cohort (n = 30) (9.0 vs. 8.3 months, P = 0.862). The survival outcomes of patients with synchronous primary esophageal squamous and gastric cancers were not worse than those of patients with isolated esophageal cancer or isolated gastric cancer.
本研究调查了同步原发性食管鳞状细胞癌和胃腺癌患者的治疗及生存结局。回顾性分析了1995年至2012年在本机构接受治疗的10783例原发性食管鳞状癌患者的病历。采用Kaplan-Meier法计算总生存率(OS)。发病率为0.38%(41/10783)。这41例患者中,26例行根治性手术,10例接受姑息性化疗或放疗,5例未接受治疗。手术组、姑息治疗组和未治疗组的中位OS分别为17.1个月、9.0个月和3.8个月。手术组的1年、3年、5年和10年OS率分别为77%、45%、33%和19%。手术组与孤立性食管癌历史队列(n = 186)(17.1对21.0个月,P = 0.061)或孤立性胃癌历史队列(n = 51)(17.1对28.9个月,P = 0.875)之间,以及姑息治疗组与其相应历史队列(n = 30)(9.0对8.3个月,P = 0.862)之间,中位OS均未观察到显著差异。同步原发性食管鳞状癌和胃癌患者的生存结局并不比孤立性食管癌或孤立性胃癌患者差。